Treatment of hodgkin’s disease with chemotherapy Based-Regimens: Long-term follow-up results with 295 patients

Objective Hodgkin’s disease (HD) is a chemo and radio -sensitive hematologic malignancy At the present time, improvement of its cure rate, reduction ol its long -term detrimental effects, and maintenance of a good quality of life are the major concerns in the treatment of HD. In this study the results of a long -term follow -up from our cancer center was analyzed retrospectively in terms of efiicacy and collateral side effects. Methods The results were analyzed for 295 patients with histologically-verified HD who were treated from 1970 to 2000, especially 182 patients treated from 1980 to 2000. Multivariant analysis (COX model ) was employed to elucidate the prognostic determinants. Results The 5, 10 and 20 -year survival for 295 patients with HD were 63.5%. 55.8% and 47.1% respectively with a median survival time of 172 months (28-352 months ). The median follow-up time was 43 months (17-352 months). The 5, 10 and 20 years overall survival and disease -free survival were 79 6%, 74.5%, 66.8% and 74 5%, 69.4%, 69.4% respectively for patients treated by regular chemotherapy and radiotherapy from 1980 to 2000. The incidence of late toxicities was low. An age of ≥45 years, B symptoms and stage III / IV were the main prognostic determinants (P = 0.000. P =0.035 and P =0.047) in this clinical study. Stage I/II and nodular sclerosis were favorable factors in comparison with stages III/IV and other histologic subtypes. Conclusions A chemotherapy-predominant modality plays an important role in the treatment of HD with promising long -term survival and fewer late toxicities. Further investigation lot this simplified convenient comprehensive therapy is warranted.